Unknown

Dataset Information

0

Activation of p53/miR-34a Tumor Suppressor Axis by Chinese Herbal Formula JP-1 in A549 Lung Adenocarcinoma Cells.


ABSTRACT: Lung cancer is the leading cause of cancer death worldwide; the most common pathologic type is lung adenocarcinoma (LADC). In spite of the recent progress in targeted therapy, most LADC patients eventually expired due to the inevitable recurrence and drug resistance. New complementary agent with evidence-based molecular mechanism is urgently needed. MiR-34a is an important p53 downstream tumor suppressor, which regulates apoptosis, cell-cycle, EMT (epithelial mesenchymal transition), and so forth. Its expression is deficient in many types of cancers including LADC. Here, we show that a Chinese herbal formula JP-1 activates p53/miR-34a axis in A549 human LADC cells (p53 wild-type). Treatment with JP-1 induces p53 and its downstream p21 and BAX proteins as well as the miR-34a, resulting in growth inhibition, colony formation reduction, migration repression, and apoptosis induction. Accordingly, the decreases of miR-34a downstream targets such as CDK6, SIRT1, c-Myc, survivin, Snail, and AXL were observed. Moreover, JP-1 activates AMPK? and reduces mTOR activity, implying its inhibitory effect on the energy-sensitive protein synthesis and cell proliferation signaling. Our results show that JP-1 activates p53/miR-34a tumor suppressor axis and decreases proteins related to proliferation, apoptosis resistance, and metastasis, suggesting its potential as a complementary medicine for LADC treatment.

SUBMITTER: Yao CJ 

PROVIDER: S-EPMC5203917 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Activation of p53/miR-34a Tumor Suppressor Axis by Chinese Herbal Formula JP-1 in A549 Lung Adenocarcinoma Cells.

Yao Chih-Jung CJ   Chow Jyh-Ming JM   Lin Pei-Chun PC   Hu Tsai-Shu TS   Kuo Hui-Ching HC   Huang Jhy-Shrian JS   Bai Kuan-Jen KJ   Lai Gi-Ming GM  

Evidence-based complementary and alternative medicine : eCAM 20161218


Lung cancer is the leading cause of cancer death worldwide; the most common pathologic type is lung adenocarcinoma (LADC). In spite of the recent progress in targeted therapy, most LADC patients eventually expired due to the inevitable recurrence and drug resistance. New complementary agent with evidence-based molecular mechanism is urgently needed. MiR-34a is an important p53 downstream tumor suppressor, which regulates apoptosis, cell-cycle, EMT (epithelial mesenchymal transition), and so fort  ...[more]

Similar Datasets

| S-EPMC5226533 | biostudies-literature
| S-EPMC3945416 | biostudies-literature
2019-10-31 | E-MTAB-8151 | biostudies-arrayexpress
| S-EPMC9613927 | biostudies-literature
| S-EPMC9360842 | biostudies-literature
| S-EPMC9071449 | biostudies-literature
| S-EPMC4085050 | biostudies-literature
| S-EPMC3746195 | biostudies-literature
| S-EPMC6763763 | biostudies-literature